Z. Kirtava et al., CD4-LYMPHOCYTOPENIA WITHOUT HIV-INFECTION - INCREASED PREVALENCE AMONG PATIENTS WITH PRIMARY SJOGRENS-SYNDROME( T), Clinical and experimental rheumatology, 13(5), 1995, pp. 609-616
Objective. Primary Sjogren's syndrome (1 degrees SS) is an autoimmune
disease, usually accompanied by manifest immune hyperactivity. In some
cases the disease converts to malignant neoplasia. On the other hand,
there are clinical similarities to HN infection. Since the I-are phen
omenon of persistent depletion of CD4+ T-lymphocytes in peripheral blo
od without HIV infection was recently defined as idiopathic CD4+ T-lym
phocytopenia (ICL), we have used the ICL criteria to investigate the p
revalence of this phenomenon among 1 degrees SS patients. Methods. Dur
ing the period 1988-94, 115 caucasian patients (10 males), mean age 57
.8 (range 19 - 82) years, with 1 degrees SS were prospectively studied
Lymphocyte subsets were investigated by means of monoclonal antibodie
s and flow cytometry. For the detection of HIV and HTLV antibodies, we
used an enzyme immunoassay (for HIV-1 and HIV-2), Western blot techni
ques (HN-I, HIV-2, HTLV-I and HTLV-II), and the polymerase chain react
ion procedure (HIV-1, HTLV-I and HTLV-II). HN antigens were tested for
with the HN-I p-24 Ag test. Results. Six patients with 1 degrees SS f
ulfilled the criteria for ICL. While the clinical condition of 5 of th
ose six patients remained stable, one patient developed malignant lymp
homa three years after her disease was classified as a case of ICL. Th
e prevalence of ICL among our 115 patients with 1 degrees SS was 5.2%,
which is significantly higher than the rates reported for arty other
patient or population group. We have estimated the relative risk of IC
L in 1 degrees SS patients to vary from 3.4 to 6,000 (P values of 0.00
01 - 0.025). Conclusion. We suggest that subjects with ICL should be c
arefully examined for 1 degrees SS and, if its presence is confirmed,
that they should be followed with regard to the possible complications
of this disease, including the development of malignant lymphoma.